Clinical Trials Logo

Hypogonadism clinical trials

View clinical trials related to Hypogonadism.

Filter by:

NCT ID: NCT02110368 Completed - Clinical trials for Hypogonadotropic Hypogonadism

Bioequivalence Study of Test and Reference Testosterone Topical Gel, 1.62% Metered Pump in Testosterone Deficient Adult Male Subjects Under Fasting Conditions

Start date: March 2014
Phase: Phase 3
Study type: Interventional

Bioequivalence study comparing the rate and extent of testosterone absorption for a test formulation versus the reference product.

NCT ID: NCT02102646 Completed - Prostate Cancer Clinical Trials

MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism

Start date: April 2014
Phase: Phase 4
Study type: Interventional

The purpose of this study is to investigate if androgen deprivation therapy in men with prostate cancer increases hepatic fat content and changes visceral/subcutaneous fat distribution.

NCT ID: NCT02082197 Withdrawn - Hypogonadism Clinical Trials

An Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men

Start date: March 2014
Phase: Phase 3
Study type: Interventional

This is an open-study with a 26 week open label treatment period followed by an optional 26 week open label extension. The total treatment period will be 52 weeks.

NCT ID: NCT02081300 Completed - Male Hypogonadism Clinical Trials

Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or Hypogonadism

SOAR
Start date: February 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of an oral testosterone undecanoate formulation for use as testosterone-replacement therapy in men with low testosterone.

NCT ID: NCT02062307 Completed - Insulin Resistance Clinical Trials

Bone Mineral Markers in Hypogonadism

Start date: August 2012
Phase: N/A
Study type: Observational

The aim of this study is to investigate the markers of bone mineral metabolism in an unconfounded group of patients with hypogonadism and to search for a relationship between endothelial dysfunction and insulin resistance.

NCT ID: NCT02042638 Completed - Clinical trials for Idiopathic Hypogonadotropic Hypogonadism

The Effects of Gonadotropin Replacement Therapy in Patients With Hypogonadism

Start date: January 2011
Phase: N/A
Study type: Observational [Patient Registry]

Effects of hCG replacement therapy on metabolic syndrome parameters in hypogonadotrophic hypogonadism.

NCT ID: NCT01993225 Completed - Clinical trials for Secondary Hypogonadism

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

Start date: January 2014
Phase: Phase 3
Study type: Interventional

This is a Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men with Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment with 12.5 mg or 25 mg Androxal or AndroGel 1.62%.

NCT ID: NCT01993212 Completed - Clinical trials for Secondary Hypogonadism

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

Start date: January 2014
Phase: Phase 3
Study type: Interventional

This is a Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men with Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment with the 12.5 mg or 25 mg Androxal or AndroGel 1.62%.

NCT ID: NCT01976728 Completed - Clinical trials for Primary Amenorrhea With Hypogonadotropic Hypogonadism

LutrePulse Hypogonadotropic Hypogonadism

Start date: April 1, 2014
Phase: Phase 3
Study type: Interventional

To compare the ovulation rate in women with primary amenorrhea with hypogonadotropic hypogonadism following pulsatile gonadotropin-releasing hormone (GnRH) treatment using the OmniPod pump versus placebo

NCT ID: NCT01952782 Recruiting - Clinical trials for Hypogonadotropic Hypogonadism

Neuropeptides in Human Reproduction

Start date: April 30, 2014
Phase: Phase 1
Study type: Interventional

The investigators are seeking healthy volunteers and volunteers with reproductive disorders for the study of the role of dynorphin in the reproductive system. Dynorphin is a naturally occurring opioid hormone that is blocked by naloxone. We hypothesize that naloxone, by blocking dynorphin, will stimulate production of gonadotropin-releasing hormone (GnRH) and kisspeptin, two other naturally occurring reproductive hormones.